RxSight Inc
$14.5M 7,552 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Otsuka America Pharmaceutical, Inc.
Otsuka America Pharmaceutical, Inc. reported $14,521,670.06 across General Payments, Research, and Ownership to 186,436 physicians and teaching hospitals across 186,436 transactions.
- $14.5M Top 10% payer
- All-tracks total
- 186,436 Top 1% volume
- Transactions
- 186,436 Top 1% reach
- Recipients
- +$667.7K
- General Payments vs PY2023
Otsuka America Pharmaceutical, Inc. reported $14,521,670.06 across all CMS Open Payments tracks (General + Research + Ownership) to 186,436 physicians and teaching hospitals in Program Year 2024 - ranking #129 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $14,521,670.06, averaging $77.89 per recipient.
How Otsuka America Pharmaceutical, Inc.'s $14.5M all-tracks total breaks down
Otsuka America Pharmaceutical, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
A
100/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
A
100/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer otsuka-america-pharmaceutical-inc Otsuka America Pharmaceutical, Inc.
$14.5M · #129/1,925 · 0.1% industry · PY2024
- TOT $14.5M
- RANK #129
- SHARE 0.1%
- TXN 186,436
- RCP 186,436
- CAT 8
- GEN $14.5M
- ΔGEN +$667.7K
- TOP1 1.8%
- PY 2024
Volume peers
Nearest volume peer: RxSight Inc ($14.5M)
Otsuka America Pharmaceutical, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Otsuka America Pharmaceutical, Inc.'s CMS-reported General Payments increased by $667.7K (+4.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OTSUKA AMERICA PHARMACEUTICAL, INC.PY2023: OTSUKA AMERICA PHARMACEUTICAL, INC.PY2024: Otsuka America Pharmaceutical, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $13,853,960.85
- PY2024
- $14,521,670.06
What the Data Shows for Otsuka America Pharmaceutical, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Otsuka America Pharmaceutical, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Compensation for Services Other Than Consulting" leads the 8-category general-payment breakdown below at $8.0M (55.1% of General Payments, 3,595 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 8 types of general payments, Otsuka America Pharmaceutical, Inc.'s largest category was "Compensation for Services Other Than Consulting" at $8.0M - 55.1% of General Payments.
Otsuka America Pharmaceutical, Inc. reports 8 general-payment categories - the top three are Compensation for Services Other Than Consulting (55.1%), Food and Beverage (30.4%), and Travel and Lodging (8.1%). The remaining 5 categories make up 6.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Otsuka America Pharmaceutical, Inc. files across 8 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Otsuka America Pharmaceutical, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $8.0M | 3,595 | 55.1% |
| Food and Beverage | $4.4M | 176,914 | 30.4% |
| Travel and Lodging | $1.2M | 5,557 | 8.1% |
| Consulting Fee | $620.2K | 181 | 4.3% |
| Grant | $267.1K | 2 | 1.8% |
| Space Rental or Facility Fees | $30.2K | 18 | 0.2% |
| Charitable Contribution | $3.2K | 14 | 0.0% |
| Education | $1.1K | 155 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $913,719.66 (6.3%) of $14,521,670.06 in this company's General Payments records across 54,674 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Otsuka America Pharmaceutical, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Langley Porter Psychiatric Hospital
$266,050.75 across 2 reported transactions
- 2
Rebecca Roma
$172,512.46 across 253 reported transactions
- 3
Charles Nguyen
$171,302.83 across 252 reported transactions
- 4
Leslie Citrome
$152,997.30 across 192 reported transactions
- 5
Amita Rajesh Patel
$150,856.32 across 154 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Otsuka America Pharmaceutical, Inc. ranks #129 of 1,925 by total payments (top 7% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,794 of 1,838 by HHI (bottom 2% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Dilon Technologies, Inc. : $148.5K total payments, HHI 35
- Boehringer Ingelheim Pharmaceuticals, Inc. : $17.9M total payments, HHI 34
- Inspire Medical Systems, Inc. : $3.9M total payments, HHI 34
- Hologic Sales and Service, LLC : $1.2M total payments, HHI 33
- CooperVision Inc. : $2.5M total payments, HHI 33
- AngioDynamics, Inc. : $17.3M total payments, HHI 33
- Otsuka America Pharmaceutical, Inc. (this company) : $14.5M total payments, HHI 33
- Salix Pharmaceuticals, a division of Bausch Health US, LLC : $4.4M total payments, HHI 33
- Inogen, Inc. : $40.6K total payments, HHI 32
- Hospira, Inc. : $21.6K total payments, HHI 31
- Hydrofera LLC : $38.2K total payments, HHI 31
- Galderma Laboratories, L.P. : $16.5M total payments, HHI 29
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Otsuka America Pharmaceutical, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Otsuka America Pharmaceutical, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Otsuka America Pharmaceutical, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
NovApproach Spine, LLC
$14.5M 178 recipients
Compare payment profiles
Swedish Orphan Biovitrum Ab
$14.7M 55 recipients
Compare payment profiles
Otsuka Pharmaceutical Development & Commercialization, Inc.
$14.8M 4,515 recipients
Compare payment profiles
Roche Diagnostics Operations, Inc.
$14.9M 0 recipients
Compare payment profiles
Argenx US, Inc.
$14.1M 19,529 recipients
Compare payment profiles
Put this to use
Otsuka America Pharmaceutical, Inc. ranks #129 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Otsuka America Pharmaceutical, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Otsuka America Pharmaceutical, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.